Soluble receptor for advanced glycation end products as a potential biomarker to predict weight loss and improvement of insulin sensitivity by a very low calorie diet of obese human subjects.
Study Goal
The researchers aimed to determine whether serum sRAGE levels are related to weight loss and insulin resistance improvement in obese subjects following a very low-calorie diet (VLCD).
Results Summary
Lower baseline sRAGE levels were significantly associated with greater BMI reduction and improved insulin resistance. Changes in sRAGE levels during the intervention correlated with changes in BMI, suggesting sRAGE as a potential biomarker for predicting dietary intervention outcomes.
Population
22 severely obese subjects (median BMI: 44.5 kg/m²).
Effective Dosage
800 kcal/day (VLCD phase).
Duration
6 months (12 weeks VLCD, 12 weeks weight maintenance).
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
very low calorie diet (VLCD) | decrease | body weight | 22 severe obese subjects | 21.7kg | reduction | #1 |
very low calorie diet (VLCD) | decrease | insulin resistance | 22 severe obese subjects | - | significant improvement | #2 |
- | decrease | sRAGE serum levels | 22 severe obese subjects | - | significantly inversely related | #3 |
- | decrease | sRAGE serum levels | 22 severe obese subjects | - | significantly inversely related | #4 |
- | decrease | sRAGE serum levels at baseline | study subjects with greater reduction of BMI | - | significantly lower | #5 |
- | decrease | HOMA reduction | subjects with lower sRAGE serum levels at baseline | - | significantly greater | #6 |
very low calorie diet (VLCD) | decrease | changes of sRAGE serum levels | 22 severe obese subjects | - | significantly correlated | #7 |
INTRODUCTION: Obesity is associated with low-grade systemic inflammation which is thought to trigger the development of comorbidities such as type 2 diabetes. The soluble receptor for advanced glycation end products (sRAGE) belongs to the innate immune system and has been linked to obesity, recently. The aim of the present study was to examine whether serum sRAGE concentrations are related to the grade of weight loss and improvement of insulin resistance due to a very low calorie diet (VLCD). METHODS: 22 severe obese subjects (Median Body Mass Index (BMI): 44.5kg/m(2)) were included in a dietary intervention study of 6month, consisting of a very low calorie formula diet phase (VLCD: 800kcal/d) for 12 weeks and a following 12 week weight maintenance phase. Fasting glucose, fasting insulin, adiponectin, leptin and sRAGE were determined from sera. Insulin sensitivity was estimated by Homeostasis Model Assessment (HOMA) index and leptin-to-adiponectin-ratio (LAR). RESULTS: Mean body weight reduction by VLCD accounted to 21.7kg with a significant improvement of insulin resistance. At baseline, sRAGE serum levels were significantly inversely related to BMI (rS=-0.642, p=0.001) and HOMA (rS=-0.419, p=0.041). Of interest, sRAGE serum levels at baseline were significantly lower in study subjects with greater reduction of BMI (p=0.017). In addition, a significantly greater HOMA reduction was observed in subjects with lower sRAGE serum levels at baseline (p=0.006). Finally, correlation analysis revealed, that changes of sRAGE serum levels were significantly correlated to changes of BMI (rS=-0.650, p=0.022) during intervention. CONCLUSION: Anti-inflammatory sRAGE might be a potential future biomarker to predict weight loss and improvement of insulin resistance by a VLCD whereby lower baseline sRAGE serum levels indicate a better outcome of the dietary intervention.